An article published recently in the journal Nutrition, Metabolism & Cardiovascular Disease revealed the results of a clinical trial of overweight and obese individuals which found a benefit for resveratrol in improving flow-mediated dilatation (FMD), a biomarker of endothelial function and cardiovascular health.*
For their research, 19 overweight or obese men and postmenopausal women with borderline hypertension were given 30, 90, or 270 milligrams resveratrol or a placebo over 4 weekly intervals, and plasma resveratrol and flow-mediated dilatation of the brachial artery were measured one hour later.
Plasma resveratrol increa-sed with dosage, corresponding to improvements in flow-mediated dilatation compared to placebo.
“The present study is the first to demonstrate that synthetic trans-resveratrol can improve FMD acutely and in a dose-related manner in at-risk population groups,” the authors announce.
“However, even the lowest resveratrol dose (30 mg) used in this study cannot be obtained from normal dietary habits.”
Editor’s note: While it is true that a normal diet does not provide this level of resveratrol, over the counter resveratrol supplements make it easy to obtain the dosages administered in the study.